# Cardiomyopathy PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/cardiomyopathy

> Cardiomyopathy, sponsored by Lexeo Therapeutics, Inc. (LXEO): 3 recorded catalysts.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | cardiomyopathy |
| Codes |  |
| Sponsor | Lexeo Therapeutics, Inc. (LXEO) https://sec-api.dev/companies/lxeo/catalysts |
| Indications | fa cardiomyopathy, [friedreich ataxia](https://sec-api.dev/indications/friedreich-ataxia) |
| Modality |  |
| FDA designations | breakthrough, fast track, orphan, rmat |

## Timeline

### Apr 2024: trial start

- Status: completed. Date confidence: month. Stage: 1. Indication: FA cardiomyopathy.
- First seen 2024-11-13, last confirmed 2026-08-12.
- SEC Form 10-Q (accession 0001193125-26-345724): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000119312526345724/lxeo-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-215678): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000119312526215678/lxeo-20260331.htm
- SEC Form 10-K (accession 0001193125-26-132085): "In April 2024, we entered into a third license agreement with Cornell University, or the Cornell Third License Agreement, pursuant to which we obtained certain rights for FA cardiomyopathy, including an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell University on our behalf and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo, to treat FA cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm
- SEC Form 10-K (accession 0001193125-26-132085): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-265757): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000119312525265757/lxeo-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-108427): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000095017025108427/lxeo-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-068536): "We entered into a third license agreement with Cornell University, or Third Cornell License Agreement, in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000095017025068536/lxeo-20250331.htm
- SEC Form 10-K (accession 0000950170-25-043486): "In April 2024, we entered into a third license agreement with Cornell University, or the Cornell Third License Agreement, pursuant to which we obtained certain rights for FA cardiomyopathy, including an exclusive license to practice under certain patent rights generated in animal studies conducted by Cornell University on our behalf and a non-exclusive license to know-how concerning a gene therapy for FA cardiomyopathy and current and future data generated in an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo, to treat FA cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm
- SEC Form 10-K (accession 0000950170-25-043486): "We entered into a third license agreement with Cornell University in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm
- SEC Form 10-Q (accession 0000950170-24-125943): "We entered into a third license agreement with Cornell in April 2024 pursuant to which we obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell investigator-initiated Phase 1A trial of a gene therapy candidate AAVrh10.hFXN, known as LX2006 at Lexeo." https://www.sec.gov/Archives/edgar/data/1907108/000095017024125943/lxeo-20240930.htm

### April 7, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-13, last confirmed 2025-04-07.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-051345): "NEW YORK - April 7, 2025 (GLOBE NEWSWIRE) - Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, today announced positive interim data across all dose cohorts of LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy." https://www.sec.gov/Archives/edgar/data/1907108/000095017025051345/lxeo-ex99_2.htm
- SEC Form 10-Q (accession 0000950170-24-125943): "We have completed enrollment of cohort 1 and expect to provide an interim data readout from that cohort in the later part of the first quarter or early part of the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1907108/000095017024125943/lxeo-20240930.htm
- SEC Form 10-K (accession 0000950170-25-043486): "We expect to provide an interim data update in mid-2025." https://www.sec.gov/Archives/edgar/data/1907108/000095017025043486/lxeo-20241231.htm

### Jan 2026: interim data readout

- Status: completed, positive. Date confidence: month. Stage: 1/2.
- First seen 2026-03-30, last confirmed 2026-03-30.
- SEC Form 10-K (accession 0001193125-26-132085): "In January 2026, we announced positive interim data from the HEROIC Phase 1/2 clinical trial." https://www.sec.gov/Archives/edgar/data/1907108/000119312526132085/lxeo-20251231.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/cardiomyopathy.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cardiomyopathy PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/cardiomyopathy

```bibtex
@misc{secapidev_pdufa_cardiomyopathy_20261116,
  title        = {Cardiomyopathy PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/cardiomyopathy}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_cardiomyopathy_20261116","title":"Cardiomyopathy PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/cardiomyopathy","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
